Novavax Stock Rallies In Pre-Market As Company Plans To Deliver Covid-19 Vaccine By September
The company also mentioned that it anticipates commercial delivery of the protein-based vaccine in the U.S. in September, pending authorization. The
Melt Pharmaceuticals Reports First Patient Dosed In Phase 3 Program Of Its MELT-300, For Needle- And Opioid-Free Sedation In Patients Undergoing Cataract Surgery; Topline Readout Expected In Q4 2024
Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the first patient has been dosed in its Phase 3 program evaluating
Tonix Pharmaceuticals Presents Two Oral Presentations And One Poster Presentation Involving TNX-1500 At The American Transplant Congress 2024
TNX-1500 displays potential as a monotherapy or combination therapy to prevent rejection in organ transplantation in allograft and xenograft animal models Research Directed by Faculty of the Center for
Twist Bioscience Preclinical Data Detailing Discovery Of Antibody Targeting Emerging Checkpoint Inhibitor Published In The Journal PLOS ONE
TB206-001 shown to be a high-affinity, cross-reactive humanized antibody antagonist of A2AR with in vivo tumor suppressing activityTB206-001 available for out-licensingTwist Bioscience Corporation (NASDAQ:TWST), a
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Amgen announced Phase 3 trial results for Uplizna for IgG4-related disease, achieving an 87% reduction in flare risk. All key secondary endpoints were met with no new safety signals.
What’s Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.
Novo Integrated Sciences Wholly Owned Canadian Subsidiary, Acenzia, Selected To Participate In Protein Industries Canada Program To Develop Plant Based Protein Products; Project Investment Amounts Expected To Total $5.4M With Acenzia Investing $600K, P…
Project investment amounts expected to total $5.4 million with Acenzia investing $600 thousand, Protein Industries Canada investing $2.3 million, and two other partner companies investing $2.5 millionNovo Integrated
Why Is Infectious Disease-Focused Vir Biotechnology Stock Trading Higher On Wednesday?
Vir Biotechnology reports promising Phase 2 SOLSTICE hepatitis delta trial results, showing high virologic response and ALT normalization rates with tobevibart and elebsiran.
British Agency Supports Eli Lilly’s Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk’s Wegovy
NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new avenues for long-term treatment.
Edwards Lifesciences Presents 5-Year Follow Up Data From PARTNER Trials Showing Clinical Outcomes For Female And Small Annulus Patients With Transcatheter Aortic Valve Replacement At The New York Valves 2024: The Structural Heart Summit
Edwards Lifesciences (NYSE:EW) today announced the results from an analysis of data from the PARTNER Trials examining outcomes of transcatheter aortic valve replacement (TAVR) patients with a small annulus. Through